Zymeworks Announces New Director Nominee
October 16, 2023 16:30 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics, today announced...
Zymeworks Provides Corporate Update and Reports Second Quarter 2023 Financial Results
August 10, 2023 16:05 ET
|
Zymeworks Inc.
Net loss for the first six months of 2023 decreased by 45% as compared to the same period in 2022Cash resources of $431.4 million as of June 30, 2023 expected to fund planned operations through at...
Zymeworks Announces Participation in Upcoming Investor Conferences
August 01, 2023 08:30 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today...
Zymeworks To Host Second Quarter 2023 Results Conference Call
July 19, 2023 08:30 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, July 19, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today...
Zymeworks Announces Participation in Upcoming Investor Conference
July 03, 2023 08:30 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, July 03, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today...
Zymeworks Appoints New Director
June 29, 2023 16:05 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, June 29, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today...
Zymeworks Set to Join Russell 3000®, Russell 2000®, and Russell Microcap® Indexes
June 26, 2023 08:30 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, June 26, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today...
Zymeworks Announces Participation in Upcoming Investor Conferences
June 01, 2023 08:30 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, June 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today...
Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer
May 18, 2023 08:30 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, May 18, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced...
Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 08, 2023 16:05 ET
|
Zymeworks Inc.
Confirmed prior guidance on 2023 operating cash burn of between $90 and $120 million and cash runway through at least 2026, and potentially beyondNet quarterly loss decreased by 66% to $24.4 million...